Rilzabrutinib – Talk Bio

CHMP Rejects Sanofi’s Rezurock Over Clinical Data Issues, Recommends Approval of BTK Inhibitor Wayrilz

1 week ago talkbio0Tagged Autoimmune thrombocytopenia, belumosudil, cGVHD, CHMP, chronic graft-versus-host disease, Clinical Data, Inosine Triphosphate, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, regulatory approval, Rezurock, Rilzabrutinib, sanofi, Wayrilz

Sanofi; CHMP; EMA; Rezurock; Wayrilz; Belumosudil; Rilzabrutinib; chronic graft-versus-host disease; cGVHD; immune thrombocytopenia; ITP; regulatory approval; clinical data

Sanofi’s Wayrilz Receives FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

2 months ago talkbio0Tagged Approved, Autoimmune thrombocytopenia, BTK inhibitor, Inosine Triphosphate, LUNA 3 trial, Rilzabrutinib, sanofi, United States Food and Drug Administration, Wayrilz

Wayrilz; rilzabrutinib; FDA approval; immune thrombocytopenia; ITP; BTK inhibitor; Sanofi; LUNA 3 trial

Sanofi’s Rilzabrutinib Shows Promising Results in Phase III Trial for Immune Thrombocytopenia (ITP)

12 months ago talkbio0Tagged Autoimmune thrombocytopenia, BTK inhibitor, Clinical Research, Phase 3 Clinical Trials, Rilzabrutinib, sanofi

Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study

Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success

2 years ago talkbio0Tagged Acquisition (action), Biotechnology, Clinical Trials, Drug Development, Drug Industry, Investments, Phase III, Principia, Rilzabrutinib, sanofi, strategic, Success

Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.